Cutaneous B-cell lymphoma responds to rituximab: A report of five cases and a review of the literature

Leukemia and Lymphoma

Volumn 47, Issue 9, 2006, Pages 1902-1907

  Gitelson, Elena ^b   Al Saleem, Tahseen ^a   Millenson, Michael ^a   Lessin, Stuart ^a   Smith, Mitchell R ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b TEMPLE UNIVERSITY HOSPITAL   (United States)

Author keywords

B cell; Cutaneous; Lymphoma; Rituximab

Indexed keywords

CHLORAMBUCIL; CLOBETASOL; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ANAMNESIS; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RELAPSE; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL FEATURE; COMORBIDITY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HUMAN; MALE; PRIORITY JOURNAL; SKIN BIOPSY; SKIN DEFECT; SKIN LYMPHOMA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; LYMPHOMA, B-CELL; MALE; REMISSION INDUCTION; SKIN NEOPLASMS; TREATMENT OUTCOME;

EID: 33750473059     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190600688099     Document Type: Article

References (57)

1. Willemze, R and (1997) EORTC classification for primary cutaneous lymphomas: A proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer Blood, 90, pp. 354-371.
2. Willemze, R and Meijer, C. (1999) EORTC classification for primary cutaneous lymphomas: The best guide to good clinical management. European Organization for Research and Treatment of Cancer Am J Dermatopathol, 21, pp. 265-273.
3. Harris, N and (1999) World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997 J Clin Oncol, 17, pp. 3835-3849.
4. Willemze, R and (2005) WHO-EORTC classification for cutaneous lymphomas Blood, 105, pp. 3768-3785.
5. Shan, D and Ledbetter, J and Press, O. (2000) Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells Cancer Immunol Immunother, 48, pp. 673-683.
6. Shan, D and Ledbetter, J and Press, O. (1998) Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies Blood, 91, pp. 1644-1652.
7. Golay, J and (2000) Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis Blood, 95, pp. 3900-3908.
8. Harjunpaa, A and Junnikkala, S and Meri, S. (2000) Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms Scand J Immunol, 51, pp. 634-641.
9. Davis, T and (1999) Single-agent monoclonal antibody efficacy in bulky non-Hodgkin's lymphoma: Results of a phase II trial of rituximab J Clin Oncol, 17, pp. 1851-1857.
10. (1997) IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma Blood, 90, pp. 2188-2195.
11. Coiffier, B and (1998) Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study Blood, 92, pp. 1927-1932.
12. Czuczman, M and (1999) Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy J Clin Oncol, 17, pp. 268-276.
13. Czuczman, M and (2004) Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up J Clin Oncol, 22, pp. 4711-4716.
14. Vose, J and (2001) Phase II study of rituximab in combination with chop chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma J Clin Oncol, 19, pp. 389-397.
15. Feugier, P and (2005) Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: A study by the Groupe d'Etude des Lymphomes de l'Adulte J Clin Oncol, 23, pp. 4117-4126.
16. Coiffier, B and (2002) CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma N Engl J Med, 346, pp. 235-242.
17. Smith, B and (2004) Primary cutaneous B-cell lymphoma treated with radiotherapy: A comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems J Clin Oncol, 22, pp. 634-639.
18. Kirova, Y and Piedbois, Y and Le Bourgeois, J. (1999) Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases Radiother Oncol, 52, pp. 15-18.
19. Sah, A and (2004) Cutaneous B-cell lymphoma: Pathological spectrum and clinical outcome in 51 consecutive patients Am J Hematol, 75, pp. 195-199.
20. Piccinno, R and (1993) Radiotherapy of cutaneous B cell lymphomas: Our experience in 31 cases J Radiat Oncol Biol Phys, 27, pp. 385-389.
21. Ingen-Housz-Oro, S and (2004) High-dose therapy and autologous stem cell transplantation in relapsing cutaneous lymphoma Bone Marrow Transplant, 33, pp. 629-634.
22. Gellrich, S and (2005) Systemic eight-cycle anti-CD20 monoclonal antibody (rituximab) therapy in primary cutaneous B-cell lymphomas - an applicational observation Br J Dermatol, 153, pp. 167-173.
23. Heinzerling, L and (2000) Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma Arch Dermatol, 136, pp. 374-378.
24. Soda, R and (2001) Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody Acta Derm Venereol, 81, pp. 207-208.
25. Viguier, M and (2002) Cutaneous B-cell lymphoma treatment with rituximab: Two cases Ann Dermatol Venereol, 129, pp. 1152-1155.
26. Sabroe, R and (2000) Rituximab in cutaneous B-cell lymphoma: A report of two cases Br J Dermatol, 143, pp. 157-161.
27. Paul, T and (2001) Intralesional rituximab for cutaneous B-cell lymphoma Br J Dermatol, 144, pp. 1239-1243.
28. Heinzerling, L and (2000) Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma Cancer, 89, pp. 1835-1844.
29. Fink-Puches, R and (2005) Treatment of primary cutaneous B-cell lymphoma with rituximab J Am Acad Dermatol, 52, pp. 847-853.
30. Aboulafia, D. (2001) Primary cutaneous large B-cell lymphoma of the legs: A distinct clinical pathologic entity treated with CD20 monoclonal antibody (rituximab) Am J Clin Oncol, 24, pp. 237-240.
31. Brogan, B and (2003) Large B-cell lymphoma of the leg: Clinical and pathologic characteristics in a North American series J Am Acad Dermatol, 49, pp. 223-228.
32. Gellrich, S and (2001) Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients Hautarzt, 52, pp. 205-210.
33. Shapiro, M and (2002) Assessment of tumor burden and treatment response by 18F-fluorodeoxyglucose injection and positron emission tomography in patients with cutaneous T- and B-cell lymphomas J Am Acad Dermatol, 47, pp. 623-628.
34. Ghielmini, M and (2004) Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly ×4 schedule Blood, 103, pp. 4416-4423.
35. Hainsworth, J. (2004) Prolonging remission with rituximab maintenance therapy Semin Oncol, 31(1 Suppl 2), pp. 17-21.
36. Fierro, M and (2003) Systemic therapy with cyclophosphamide and anti-CD20 antibody (rituximab) in relapsed primary cutaneous B-cell lymphoma: A report of 7 cases J Am Acad Dermatol, 49, pp. 281-287.
37. Grange, F and (2004) Bcl-2 protein expression is the strongest independent prognostic factor of survival in primary cutaneous large B-cell lymphomas Blood, 103, pp. 3662-3668.
38. Grange, F and (2001) Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study J Clin Oncol, 19, pp. 3602-3610.
39. Mounier, N and (2003) Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large-B-cell lymphoma (CLBCL) Blood, 101, pp. 4279-4284.
40. Colombat, P and (2001) Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation Blood, 97, pp. 101-106.
41. Aguilera, N and (2001) Cutaneous follicle center lymphoma: A clinicopathologic study of 19 cases Modern Pathol, 14, pp. 828-835.
42. Bergman, R and (2001) Clinicopathologic, immunophenotypic, and molecular characterization of primary cutaneous follicular B-cell lymphoma Arch Dermatol, 137, pp. 432-439.
43. Mirza, I and (2002) Primary cutaneous follicular lymphoma: An assessment of clinical, histopathologic, immunophenotypic, and molecular features J Clin Oncol, 20, pp. 647-655.
44. Leinweber, B and (2004) Differential diagnosis of cutaneous infiltrates of B lymphocytes with follicular growth pattern Am J Dermatopathol, 26, pp. 4-13.
45. Cerroni, L and (2000) Primary cutaneous follicle center cell lymphoma with follicular growth pattern Blood, 95, pp. 3922-3928.
46. Hoefnagel, J and (2005) Distinct types of primary cutaneous large B-cell lymphoma identified by gene expression profiling Blood, 105, pp. 3671-3678.
47. Giannotti, B and Santucci, M. (1993) Skin-associated lymphoid tissue (SALT)-related B-cell lymphoma (primary cutaneous B-cell lymphoma). A concept and a clinicopathologic entity Arch Dermatol, 129, pp. 353-355.
48. Pimpinelli, N and Santucci, M and Giannotti, B. (1993) Cutaneous lymphoma: A clinically relevant classification Int J Dermatol, 32, pp. 695-700.
49. Hallermann, C and (2004) Molecular cytogenetic analysis of chromosomal breakpoints in the IGH, MYC, BCL6, and MALT1 gene loci in primary cutaneous B-cell lymphomas J Invest Dermatol, 123, pp. 213-219.
50. Hallermann, C and (2004) Chromosomal aberration patterns differ in subtypes of primary cutaneous B cell lymphomas J Invest Dermatol, 122, pp. 1495-1502.
51. Nouri-Shirazi, M and (2000) Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses J Immunol, 165, pp. 3797-3803.
52. Palucka, K and Banchereau, J. (1999) Linking innate and adaptive immunity Nature Med, 5, pp. 868-870.
53. Liu, Y. (2001) Dendritic cell subsets and lineages, and their functions in innate and adaptive immunity Cell, 106, pp. 259-262.
54. Selenko, N and (2002) Cross-priming of cytotoxic T cells promoted by apoptosis-inducing tumor cell reactive antibodies J Clin Immunol, 22, pp. 124-130.
55. Selenko, N and (2001) CD20 antibody (C2B8)-induced apoptosis of lymphoma cells promotes phagocytosis by dendritic cells and cross-priming of CD8+ cytotoxic T cells Leukemia, 15, pp. 1619-1626.
56. Ratzinger, G and (2004) Mature human Langerhans cells derived from CD34+ hematopoietic progenitors stimulate greater cytolytic T lymphocyte activity in the absence of bioactive IL-12p70, by either single peptide presentation or cross-priming, than do dermal-interstitial or monocyte-derived dendritic cells J Immunol, 173, pp. 2780-2781.
57. Banchereau, J and (2001) Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine Cancer Res, 61, pp. 6451-6458.